Clinical Trials Logo

KRAS Mutation-Related Tumors clinical trials

View clinical trials related to KRAS Mutation-Related Tumors.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06237413 Recruiting - Solid Tumor Clinical Trials

A Study of ZG2001 in Participants With KRAS Mutated Advanced Solid Tumours

Start date: August 10, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This study will evaluate the tolerability, safety, effects, and pharmacokinetics of ZG2001 in Participants with advanced solid tumors that have a KRAS mutation.

NCT ID: NCT05786924 Recruiting - Colorectal Cancer Clinical Trials

A Study of BDTX-4933 in Patients With KRAS, BRAF and Select RAS/MAPK Mutation-Positive Cancers

Start date: April 18, 2023
Phase: Phase 1
Study type: Interventional

BDTX-4933-101 is a first-in-human, open-label, Phase 1 dose escalation and an expansion cohort study designed to evaluate the safety and tolerability, maximum tolerated dose (MTD) and the preliminary recommended Phase 2 dose (RP2D), and antitumor activity of BDTX-4933. The study population for the Dose Escalation part of the study comprises adults with recurrent advanced/metastatic non-small cell lung cancer (NSCLC) harboring KRAS non-G12C mutations or BRAF mutations, advanced/metastatic melanoma harboring BRAF or NRAS mutations, histiocytic neoplasms harboring BRAF or NRAS mutations, and other solid tumors harboring BRAF mutations. The study population for the Dose Expansion part of the study comprises adults with recurrent advanced/metastatic NSCLC harboring KRAS non-G12C mutations. All patients will self-administer BDTX-4933 orally in 28-day cycles until disease progression, toxicity, withdrawal of consent, or termination of the study.

NCT ID: NCT05661201 Recruiting - Solid Tumor Clinical Trials

NEROFE and Doxorubicin in KRAS-mutated ST2-positive Solid Tumors

Start date: April 12, 2023
Phase: Phase 1
Study type: Interventional

The goal of this clinical trial is to learn about the safety of NEROFE and doxorubicin and how well it works in patients with advanced/unresectable or metastatic solid KRAS-mutated and ST-positive solid tumors. The main question it aims to answer is to find the recommended dose and scheduled for the combination of NEROFE and doxorubicin. Participants will receive weekly doses of NEROFE and doxorubicin.

NCT ID: NCT05631574 Recruiting - Colorectal Cancer Clinical Trials

Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer

Start date: January 12, 2023
Phase: Phase 1
Study type: Interventional

A Phase 1/1b dose finding study to determine the OBD(s) and RP2D(s) of BMF-219, a covalent menin inhibitor small molecule, in subjects with KRAS mutated unresectable, locally advanced, or metastatic NSCLC (Cohort 1), PDAC (Cohort 2), and CRC (Cohort 3).

NCT ID: NCT04916236 Recruiting - Colorectal Cancer Clinical Trials

Combination Therapy of RMC-4630 and LY3214996 in Metastatic KRAS Mutant Cancers

SHERPA
Start date: March 31, 2022
Phase: Phase 1
Study type: Interventional

This is a Phase I/Ib study in which the safety of the combination therapy of RMC-4630 and LY3214996 in the treatment of KRAS mutant cancers will be studied.

NCT ID: NCT03597581 Recruiting - Colorectal Cancer Clinical Trials

A Study of RGX-202-01 (Ompenaclid) as Combination Therapy in 2nd Line RAS Mutant Advanced Colorectal Cancer

Start date: June 5, 2018
Phase: Phase 1
Study type: Interventional

RGX-202-01 (ompenaclid) is a Phase 1, first-in-human, dose escalation and expansion study of RGX-202-01 as a single agent and in combination with FOLFIRI +/- bevacizumab. RGX-202-01 is a small molecule inhibitor of the creatine transporter SLC6a8, a novel metabolic target that drives gastrointestinal cancer progression. During the dose escalation stage, multiple doses of orally administered RGX-202-01 with or without FOLFIRI +/- bevacizumab (single agent or combination therapy) will be evaluated in patients with advanced gastrointestinal tumors (i.e., locally advanced and unresectable, or metastatic) who have had PD on available standard systemic therapies or for which there are no standard systemic therapies of relevant clinical impact. In the expansion stage: Patients with colorectal cancer (CRC) RAS Mutant will be treated at the optimal dose.